Cargando…

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

The nuclear farnesoid X receptor (FXR) regulates bile acid homeostasis and is a drug target for metabolic liver diseases. FXR also plays an important role in hepatitis B virus (HBV) DNA transcription. In vitro and in mice, FXR agonist treatment leads to inhibition of viral replication and a decline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erken, Robin, Andre, Patrice, Roy, Elise, Kootstra, Neeltje, Barzic, Noelie, Girma, Hugo, Laveille, Christian, Radreau‐Pierini, Pauline, Darteil, Raphael, Vonderscher, Jacky, Scalfaro, Pietro, Tangkijvanich, Pisit, Flisiak, Robert, Reesink, Henk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293351/ https://www.ncbi.nlm.nih.gov/pubmed/34467593 http://dx.doi.org/10.1111/jvh.13608

Ejemplares similares

Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B
por: Erken, Robin, et al.
Publicado: (2022)

Identification of a Novel HBV Encoded miRNA Using Next Generation Sequencing
por: Loukachov, Vladimir, et al.
Publicado: (2022)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients
por: Erken, Robin, et al.
Publicado: (2022)

Virus-host interactomics: new insights and opportunities for antiviral drug discovery
por: de Chassey, Benoît, et al.
Publicado: (2014)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Dynamics of the Immune Response in Acute Hepatitis B Infection
por: Stelma, Femke, et al.
Publicado: (2017)

Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin
por: Lenicek, Martin, et al.
Publicado: (2020)

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
por: He, Handan, et al.
Publicado: (2023)

Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity
por: Legrand, Anne-Flore, et al.
Publicado: (2023)

Use of Hepatitis B-e Antigen to Identify Pregnant Women With Hepatitis B Virus Infection Who Need Antiviral Therapy for Prevention of Mother-to-child Transmission
por: Jiragraivutidej, Chanya, et al.
Publicado: (2021)

Human-Centered Design of Mobile Health Apps for Older Adults: Systematic Review and Narrative Synthesis
por: Nimmanterdwong, Zethapong, et al.
Publicado: (2022)

Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection
por: Loukachov, Vladimir V., et al.
Publicado: (2022)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
por: Ahmad, Alaa, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
por: Younis, Islam R., et al.
Publicado: (2023)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Caenorhabditis Intervention Testing Program: the farnesoid X receptor agonist obeticholic acid does not robustly extend lifespan in nematodes
por: Morshead, Mackenzie L, et al.
Publicado: (2020)

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
por: Marotta, Christine, et al.
Publicado: (2022)

Hepatitis B Virus HBx Activates Notch Signaling via Delta-Like 4/Notch1 in Hepatocellular Carcinoma
por: Kongkavitoon, Pornrat, et al.
Publicado: (2016)

Regulatory Functions and Mechanisms of Circular RNAs in Hepatic Stellate Cell Activation and Liver Fibrosis
por: Nokkeaw, Archittapon, et al.
Publicado: (2023)

An innovative wireless electrochemical card sensor for field-deployable diagnostics of Hepatitis B surface antigen
por: Teengam, Prinjaporn, et al.
Publicado: (2023)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist
por: Erstad, Derek J., et al.
Publicado: (2018)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Autophagy Related-Protein 16-1 Up-Regulated in Hepatitis B Virus-Related Hepatocellular Carcinoma and Impaired Apoptosis
por: Peantum, Jiaranai, et al.
Publicado: (2018)

Changes in transient elastography in early cirrhotic patients after receiving nonselective B‐blocker for primary variceal bleeding prophylaxis: Three‐month follow up
por: Piyachaturawat, Panida, et al.
Publicado: (2018)

The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono-Infection and HCV/HIV Co-Infection
por: Kiatbumrung, Rattanaporn, et al.
Publicado: (2018)

Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals
por: Chuaypen, Natthaya, et al.
Publicado: (2019)

Acute liver failure and death predictors in patients with dengue-induced severe hepatitis
por: Teerasarntipan, Tongluk, et al.
Publicado: (2020)

Transcriptomic Analyses Reveal Long Non-Coding RNA in Peripheral Blood Mononuclear Cells as a Novel Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Kunadirek, Pattapon, et al.
Publicado: (2022)

Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis
por: NOKKEAW, ARCHITTAPON, et al.
Publicado: (2023)

Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Pinjaroen, Nutcha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_khkvn923qv7iktq2gb0s75e8bj